Sheng Tu1*†Xu Lin2†Jili Qiu3†Jiaqi Zhou1Hui Wang4Shiyao Hu5
Yihan Yao3
Yali Wang3Yongchuan Deng3
Yunxiang Zhou3*
Anwen Shao6*- 1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- 2Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- 3Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- 4Department of Medical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- 5School of Medicine, Zhejiang University, Hangzhou, China
- 6Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Glioblastoma is considered to be the most malignant disease of the central nervous system, and it is often associated with poor survival. The immune microenvironment plays a key role in the development and treatment of glioblastoma. Among the different types of immune cells, tumor-associated microglia/macrophages (TAM/Ms) and CD8-positive (CD8+) T cells are the predominant immune cells, as well as the most active ones. Current studies have suggested that interaction between TAM/Ms and CD8+ T cells have numerous potential targets that will allow them to overcome malignancy in glioblastoma. In this review, we summarize the mechanism and function of TAM/Ms and CD8+ T cells involved in glioblastoma, as well as update on the relationship and crosstalk between these two cell types, to determine whether this association alters the immune status during glioblastoma development and affects optimal treatment. We focus on the molecular factors that are crucial to this interaction, and the role that this crosstalk plays in the biological processes underlying glioblastoma treatment, particularly with regard to immune therapy. We also discuss novel therapeutic targets that can aid in resolving reticular connections between TAM/Ms and CD8+ T cells, including depletion and reprogramming TAM/Ms and novel TAM/Ms-CD8+ T cell cofactors with potential translational usage. In addition, we highlight the challenges and discuss future perspectives of this crosstalk between TAM/Ms and CD8+ T cells.
Introduction
Glioblastoma, also known as glioblastoma multiforme (GBM), is one of the most malignant diseases that is thought to originate within the central nervous system (CNS) (1). Although significant progress has been made in various treatments, such as chemotherapy, radiotherapy and surgery, the survival rate among glioblastoma patients has not shown progressive improvement using these conventional treatments (2–4). In the past few decades, there have been significant new therapeutic advances in oncology, wherein small molecules have shown promising curative effects among many types of malignant tumors. However, given the special anatomic structure of the CNS, many therapeutic molecules are not able to reach the target zone because of the blood–brain barrier (BBB), which is a highly selective barrier in the CNS (5), leading to poor survival and prognosis of patients with malignant CNS tumors.
Nonetheless, recently, immune therapy has shown promising outcomes (6–9) by overcoming the selectivity of BBB as immune cells are highly infiltrative in the tumor microenvironment of glioblastomas (10). The immune system in the CNS plays a significant role in GBM development (11). The tumor microenvironment of GBM is infiltrated with various types of immune cells and cytokines. CD8-positive (CD8+) T cells are the most important type of immune cells in immune therapy as they function as tumor cell killers. Furthermore, macrophages are the most infiltrated immune cells (12, 13) in GBM. Hence, tumor-associated macrophages (TAMs) account for the majority of macrophages within GBM, and are recruited from circulation. Most TAMs are considered to be immunosuppressive agents that are associated with tumor immune escape, as well as angiogenesis and invasion. Microglia are resident immune cells of the CNS that interact as housekeepers of the CNS and participate in the innate immune responses and antigen presentation. However, microglia are silenced in the GBM microenvironment and support immunosuppression. Given their common biological functions, microglia and macrophages in GBM tumors (as in other tumors) are known as tumor-associated microglia/macrophages (TAM/Ms) (14, 15). The crosslink between GBM-associated immune cells and TAM/Ms and CD8+ T cells, which show great potential given their direct and indirect contact with GBM cells in the immune response, can serve as a potential therapeutic target for GBM.
Herein, we outline the physiological, pathological, and micro-environment features of TAM/Ms and CD8+ T cells with regard to GBM development, as well as the impact of their crosstalk on tumor malignancy, and a potential translational scheme for glioblastoma treatment.
Role of TAM/Ms in Glioblastoma
Macrophages and microglia have a significant function in the innate immune response of a healthy brain tissue, such as in anti-inflammatory and scavenger processes (14). Microglia and macrophages are classified as neuronal support cells that are located between nerve fibers, and function to carry out the primary immune responses of the nervous system as killer cells and phagocytes. Microglia originate from the embryonic mesoderm and are located in the nerve tissue; likewise, some macrophages develop in a similar manner. However, macrophages can also be derived from monocytes that migrate from circulation to become adult macrophages (14).
In the physiological innate response of the nervous system, macrophages and microglia recognize pathogens or eliminate cells through the pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). These activate a cascade of immune response reactions that function against infection, ischemia, trauma, or other threats. As oligomeric protein complexes are activated in response to PAMPs and DAMPs, inflammasomes activate and release inflammatory cytokines, including IL-1β and IL-18. Various inflammasomes, inflammatory cytokines, and chemokines play contrasting roles with regard to cancer development and progression. Macrophages and microglia are classified into M1 and M2 clusters that represent pro-inflammatory and anti-inflammatory components, respectively. Pro-inflammatory cytokines are commonly categorized in relation to the M1 phenotype, and include interferon-gamma (IFN-γ), tumor necrosis factor-α (TNF-α), IL-2, and IL-12. In contrast, immunosuppressive molecules, such as IL-4, IL-10, IL-13, and tumor growth factor-β (TGF-β), are classified in relation to the M2 phenotype (16–19). Notably, within the tumor microenvironment, TGF-β plays crucial roles with regard to tumor immunity, and targeted TGF-β signaling blockade in helper T cells elicits an effective tissue-level cancer defense response that can provide a basis for therapies that are directed toward the cancer microenvironment (20); TGF-β is also the most potent immunosuppressor against cancer cells, and this significant effect is mediated in multiple ways, including polarization of macrophages to M2 cells. Additionally, several previous studies have indicated that anti-TGF-β exerts a potential and promising effect on tumor immunity (21–24). The relative literature on TGF-β indicates that TGF-β likely also plays an important role in the regulation of pathological processes in GBM patients. Moreover, a therapy targeting TGF-β can serve as a potential strategy in GBM treatment in the future. Recently, additional biomarkers have been described to play a role in macrophage polarization. TNF-α, IL-12, and IL-23 have all been confirmed to be related to the M1 phenotype (14, 25). Inducible NO synthase (iNOs) has been shown to be associated with M2 clusters in GBM cells (26). Together with a certain polarization proportion, M1 and M2 clusters of macrophages and microglia help maintain CNS homeostasis. Although M1 and M2 phenotypes are different owing to levels of differentiation, they have plasticity to a certain extent, and TAM/Ms show overlapped proportion between M1 and M2 clusters (27, 28).
With regard to GBM, TAM/Ms have common biomarkers, e.g., cluster of differentiation 68 (CD68), which is also the most commonly expressed protein in various malignant diseases (29). Nevertheless, CD163, which is highly specific for M2 macrophages, is also highly expressed in GBM cells (29–31), which suggests a dominance of the M2 cluster of TAM/Ms in the GBM tissue. In an early study on GBM-related macrophages, M1 and M2 clusters were classified together as being histologically similar to each other. Studies have indicated that the inclusion of TAM/Ms into the M2 family is responsible for their non-phagocytic function and anti-immune responses in GBM; TAM/Ms are further classified into M2a, M2b, and M2c subtypes based on their different roles in GBM response. However, specific exclusive characteristics of the M2 family between categories remains to be further elucidated (15). The M1 and M2 polarity classification is defined in the inflammatory response. However, TAM/Ms in GBM play a role in the carcinogenesis process. Differences in the origin of macrophages and activation of the innate immune response induces different responses, dependent on the microenvironment, helping the formation of heterogeneous communities and subgroups with appropriate functions. In the GBM microenvironment, the predominant activity of TAM/Ms takes place through the M2 phenotype, whereas the immune status of TAM/Ms favors immune suppression. Moreover, the enrichment of the M2 cluster TAM/Ms is associated with the prognosis and survival of GBM patients (32–34). From a biochemistry perspective, GBM cells produce immunosuppressive cytokines, including IL-10 (35), macrophage-inducing chemokine monocyte chemotactic protein-1 (CCL2) (16), and cell-surface protein colony-stimulating factor 1 receptor (CSF1R) (36). Transcriptomic analysis of GBM cells has demonstrated a positive relationship between invasion-related genes and immunosuppressive genes (37, 38). Hence, polarized TAM/Ms have been reported to stimulate carcinogenesis via their immune-escape effect and immunosuppressive secretions. Further, cancer growth factors have also been identified in GBM cells co-cultured with TAM/Ms (25). With the help of these growth factors, GBM cells are able to suppress TAM/M polarization into the M1 phenotype and induce polarization into the M2 phenotype by recruiting and re-differentiating macrophages into M2-dominant clusters, thus creating a pro-carcinogenesis immunosuppressive environment.
Previous studies have validated that TAM/Ms are related to the prognosis/survival outcomes of GBM patients. One previous study (39) used automated quantitative immunofluorescence to identify the prognostic impact of TAMs in GBM. The results of their study suggested that M2-like TAMs hold an unfavorable prognostic value in high-grade gliomas. Similarly, Pimenta et al. (40) reported that untreated GBM patients with TAM infiltration demonstrated a shorter overall survival compared with the patients without TAM infiltration. Additionally, the number of microglia/macrophages with positive staining for CD163 and CD204, which are thought to be markers for M2 macrophages, was found to be correlated to the histological grade of gliomas, whereas the ratio of M2 macrophages in the TAM/Ms was related to the histological grade (41). This suggests that evaluation of the proportion of M2 microglia/macrophages in GBM is useful for the assessment of the prognosis of patients with gliomas, including GBM. Kaffes et al. (42) determined that high expression of the TAM-related gene AIF1, which encodes the TAM-specific protein IBA1, is correlated with a worse prognosis in pro-neural GBM, but confers a survival benefit in mesenchymal tumors. Recently, numerous studies have reported that TAM/Ms regulation may be a potential therapy strategy in cases with GBM. A new report demonstrated that PI3Kγ inhibition could suppress TAM/M accumulation in glioblastoma microenvironment, and enhance the anti-neoplastic effects of temozolomide in glioblastoma cells (43). In addition, the deletion of HuR (an RNA regulator) in TAM/Ms could attenuate glioma growth (44). Further, Martins et al. provide a comprehensive overview of microglia-centered combinatorial strategies against glioblastoma, and conclude that MG modulation, as a central paradigm in GBM immune tumor microenvironment, may lead to additional, long-lasting, and effective tumoricidal responses (45).
Altogether, TAM/Ms appear to be involved in the development of GBM via atypical polarization and by creating an immunosuppressive microenvironment, and are tightly associated with the outcome of GBM patients. Thus, we can infer that TAM/M polarization, recruitment, and function of immunosuppressive cytokines may be potential targets in GBM treatment.
Role of CD8-Positive T Cells in Glioblastoma
CD8+ T cells are a subtype of T cells that develop within the thymus and have a cytotoxic effect on cancer cells through antigen recognition using major histocompatibility complex class I (MHC-1) (46). In cases of carcinoma, CD8+ T cells are characterized to be able to kill cancer cells directly at the end of their cancer immune response at any phase of malignancy.
There are three steps involved in the differentiation of naïve T cells into cytotoxic CD8+ T cells, which leads to a cytotoxic effect on GBM and other cancers. First, the immunogenic antigens that are aberrantly expressed are processed through antigen-presenting cells, such as dendritic cells (DC), and presented to naïve T cells at peripheral lymphatic sites, such as lymph nodes. Activated CD8+ T cells then go on to proliferate clonally and migrate to the GBM site, where CD8+ T cells recognize tumor cells through MHC-1 and release cytotoxic signals that initiate the anti-tumor effect. Traditionally, the central nervous system is considered to be an immune-exempted organ. Recently, many studies have identified that under pathological conditions, the integrity of the BBB and the blood–cerebrospinal fluid barrier are compromised, causing inflammatory cells to enter the brain and activate the immune system (47, 48). However, CD8+ T cell infiltration varies widely between different types of GBMs. An in vivo study demonstrated a substantially increased infiltration of CD8+ T cells in mesenchymal GBM, whereas immune infiltrates were rarely found in pro-neural GBM. Furthermore, the molecular subtype of cancer stem cells (CSCs) TGF-β-dependently contributed to the degree of immune infiltration in patients with GBM (49). Cancer vaccination has been developed to amplify this anti-cancer cytotoxic effect by CD8+ cells (9). However, glioblastoma can escape from natural immune response by immune inhibition. To overcome this challenge, immune checkpoint therapy has been developed that can help boost anti-cancer immune response (6). However, in some cases, GBM may undergo immune escape by not presenting tumor antigens or MHC-1, thus preventing recognition by CD8+ T cells. Genetic modification is another promising method that involves adaptively transferring target antigens to CD8+ T cells and cultivating them clonally. These CD8+ T cells, known as chimeric antigen receptor T cells (CAR-T), have the ability to recognize immune-escaped tumor cells (50, 51).
Various studies have assessed the importance of CD8+ T cells with regard to outcomes of GBM patients. Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against GBM. Although the recent phase II “GBM-Vax” trial shows no clinical efficacy of Audencel, as assessed through progression-free and overall survival of GBM patients, post-vaccination levels of CD8+ T cells in the blood were indicative of a significantly better survival among GBM patients (52). A report by Yang et al. (53), which included 519 GBM patients, suggested that tumors from long-term survivors, more likely than those form short-term survivors, have either intermediate or extensive CD8+ T cells infiltrates compared with focal or rare infiltrates. This indicates that prolific CD8+ T cell infiltrates appear to correlate with partitioned long-term survival among newly diagnosed GBM patients. Also, increased CD8+ to FoxP3+ regulatory T cell ratios showed a positive correlation with survival outcomes in primary GBM, indicating that absolute numbers of CD8+ T-cells and effective balance of CD8+ T cells to FoxP3+ regulatory cells are both informative for predicting clinical outcomes in patients with GBM (54).
Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8+ T Cells
During cancer development, tumor tissue is infiltrated by various immune response cells that can be classified into either immune-effector cells or immune-supporting cells. Among tumor-associated immune cells in GBM, CD8+ T cells are known to be major cytotoxic lymphocytes (CTLs) and TAM/Ms are the most infiltrated immune-supporting cells (55).
The dominant effect of TAM/Ms in GBM is immunosuppression, which is manifested through the expression of PD-L1 and PD-L2, as well as the CTL-associated protein 4 (CTLA-4) ligands CD80 and CD86. The main target of these immune checkpoints is CD8+ T cells, which leads to the inhibition of its cytotoxic effects. To expand into the therapeutic scenario, as in the case of immune checkpoint therapy, there are still several patients who do not respond to immune checkpoint inhibitors (8, 56). An ideal theoretical explanation for this may be that CD8+ T cells need to overcome an intrinsic negative regulation of the immune system. In cases of GBM, TAM/M-induced immunosuppression is one of the major reasons for passive response toward immune checkpoint therapy. In vivo studies have determined that TGF-β secreted by TAM/Ms inhibits T cell-mediated tumor clearance (57). Next, TGF-β targets proteins that are responsible for CTL-mediated tumor cytotoxicity, including perforin, granzyme A, granzyme B, first apoptosis signal ligand (FASL), and IFN-γ. While IFN-γ is the main trigger of cytotoxic activity, FASL is the key element that activates apoptosis of target cells. Neutralization of TGF-β through an antagonist in a mouse model has been shown to upregulate cytotoxic gene expression among CD8+ T cells (57). In contrast, TAM/M-originated TGF-β also causes differentiation of naïve T cells to regulatory T (Treg) cells, which is another CD8+ suppressor in the tumor microenvironment (58). Moreover, IL-10 secretion by TAM/Ms also stimulates Treg differentiation (59). A study by Takenaka et al. (60) reported that kynurenine produced by GBM cells activates aryl hydrocarbon receptor (AHR) in TAMs, which helps modulate their function and T-cell immunity. AHR drives the expression of the ectonucleotidase CD39 in TAMs, which promotes CD8+ T cell dysfunction by producing adenosine in conjunction with CD73, AHR, and CD39 expressed in TAMs. This participates in the regulation of the immune response, including CD8+ T cell regulation in GBM, and constitutes potential targets for immunotherapy.
TAM/Ms also play a significant role with regard to infiltration of CD8+ T cells in malignant tumors. Fibrosis is a major target for TAM/Ms to regulate CD8+ T cell migration (61, 62), led by extracellular matrix stiffness and collagen deposition. CCL2, produced in the glioma microenvironment, is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells (63), as well as macrophages that are dependent on colony stimulating factor-1 (CSF-1) for both differentiation and survival (64). Therefore, TAM depletion via CCL2 or CSF-1 inhibitors have been reported to increase CD8+ T cell migration and infiltration (65) as it helps overcome immunosuppression.
In addition, TAM/Ms are able to regulate T cell metabolism. Arginase belongs to a family of L-arginine enzymes and regulates arginine metabolism. Arginase overexpression by TAM/Ms leads to metabolic starvation of T cells through indoleamine 2,3-dioxygenase (IDO) pathway (59, 66).
Moreover, in melanoma and pancreatic cancer, TAM/Ms are able to intervene in CD8+ T cell function by expressing V-domain Ig suppressor of T cell activation (VISTA), which causes a suppressive CD8+ T cell response (67).
Interactions between TAM/Ms and CD8+ T cells are known to be involved across all stages of GBM development, including infiltration, differentiation, and tumor cell interaction. This complexity of the immune microenvironment interplay causes the heterogeneity of GBM tissue across different patients. Based on this, there are many promising treatment targets for GBM that are likely helpful for patients who cannot benefit from the current standard treatment of GBM (Figure 1).
Figure 1 Crosstalk between tumor associated macrophages (TAMs) and CD8-positive (CD8+) T cells. Most TAMs function as tumor suppressive agents. TAMs create an immunosuppressive microenvironment through a sophisticated network. The classical pathway to inhibit CD8+ T cell function is through immune checkpoint recognition. TAMs present immune inhibition signals, such as programed cell death protein (PD-1) pathway or cytotoxic T-lymphocyte-associated protein 4 (CTLA4) pathways, which hamper CD8+ activation. TAMs also recruit other immunosuppressive cells, such as regulatory T cells (Treg), by secreting IL-10 and TGFβ to negatively regulate CD8+ T cells. Studies suggest that the metabolism of CD8+ T cells can be affected by TAMs. Specifically, TAMs can lead T cell starvation though arginine metabolism. After activation of CD8+ T cells, TAMs can help influence the migration and infiltration of CD8+ T cells through extracellular matrix stiffness and collagen deposition to have an effect on cytotoxicity.
Novel Therapeutics Based on TAM/M Regulation for Enhancing Effector T Cells in Glioblastoma
Given their physiology, TAM/Ms do not have the characteristic of eliminating tumor cells directly. Individually, the ideal role of CD8+ T cells in tumor tissue is to carry out cytotoxic activity against malignant cells. Likewise, there are a few novel therapies that have tried to reverse the process of innate and adaptive immune responses that are suppressed by the tumor microenvironment, either through direct or indirect schemes. This includes immune checkpoint inhibitor (ICI) or chimeric antigen receptor T cell (CAR-T) therapy. Several ongoing clinical trials have depicted great progress in GBM treatment with ICI (56, 68) and CAR-T therapy (69, 70). However, a large number of patients still do not respond to these treatments (71), largely because of the failure of CD8+ T cells to overcome the immune inhibitory microenvironment. TAM/Ms are key cells that generate and maintain this immunosuppressive environment in GBM. There are potential treatments for GBM that underlie this crosstalk between the immune effector CD8+ T cells and the immune supporter TAM/Ms. Finally, a majority of therapies that target the regulation of TAM/Ms for enhancing effector T-cell function in GBM are based on three methods, i.e., TAM/M depletion, TAM/M reprogramming, and other novel effective biomarkers in TAM functioning.
TAM/M Depletion
To participate in the immune activity within the GBM microenvironment, TAM/Ms and other immune cells migrate and gather at the tumor site from the other tissues that are in the vicinity. As differentiated TAM/Ms do not have proliferative ability, a continuous supply of TAM/Ms is needed within the GBM microenvironment. Accordingly, activation of the CC-chemokine receptor 2 (CCR2) signal, which is located on the surface of TAM/Ms, induces the accumulation of TAM/Ms at the target site (72–75). It has been reported that astrocytes are the main cell types that express CCR2 in normal brain tissues, which helps maintain certain infiltration of macrophages and microglia to execute an innate immune response, and maintain homeostasis in the CNS environment (73, 76). GBM cells have been reported to express the CCR2 ligand to raise microglia (16), which likely enhances GBM malignancy by creating an anti-immune environment. In a mouse model of breast cancer, a CCR2 antagonist was reported to dramatically reduce macrocyte infiltration (74). The colony-stimulating factor 1 receptor (CSF1R) is also recognized to be a TAM/M recruiting signal (77). Treatment with CSF1R antagonist PLX3397 was shown to markedly reduce the number of TAM/Ms in several cancer tissues across mouse models (36, 78, 79). There are other potential targets, including the CX3CL1/CX3CR1 complex, that elicit TAM/M adhesion and migration via matrix degradation through its downstream enzyme matrix metalloproteinase 2 (MMP2), which, in turn, induces GBM invasion (80). MMP9 and MMP19 also participate in this process. CXCR4 antagonists also show an inhibition of TAM/Ms’ migration in GBM, though their main target is myeloid-originated macrophages (81).
With regard to immune checkpoint therapy, TAM/M-induced immunosuppressive environment causes dormancy of CD8+ T cells. TAM/M recruitment is one of the targets that helps revive the anti-tumor activity induced by immune checkpoint inhibitors. In a mouse with pancreatic cancer, using a CCR2 antagonist was associated with significant inhibition of macrophage infiltration into the tumor region (82). Furthermore, upon combination treatment with CCR2 antagonist and the immune checkpoint inhibitor PD-1 antibody, suppression of tumor growth was found to be more effective compared with the PD-1 antibody alone. This result suggests that TAM/M recruitment is a potential target for GBM treatment as GBM is a type of TAM/M-enriched malignant cancer. In contrast, in another study, overexpression of CCR2 in GBM aggravated microglia recruitment, which induced an invasive transition of GBM cells (76).
Treatment with the CSF1R antagonist PLX3397 also helps boost the efficacy of immune checkpoint inhibitors. Treatment with PLX3397, as well as the PD-1 antibody, depicted complete tumor growth blockage among mice with pancreatic cancer, whereas PD-1 antibody treatment alone demonstrated limited tumor inhibition (Figure 2A). Notably, an inhibitor of CSF1R that targets TAMs in a mouse pro-neural GBM model was studied, which demonstrated significantly increased survival and regression of established tumors, without TAM depletion in treated mice, thus identifying the therapeutic potential of CSF1R inhibition in GBM (64). As a negative regulator of anti-tumor immunity, TGF-β impairs the efficacy of anti-PD-1/PD-L1, and stimulates drug resistance. YM101 can help simultaneously block TGF-β and PD-L1 pathways and has a superior anti-tumor effect, compared with the monotherapies (21). In addition, the agent bintrafusp alfa is able to bring the TGF-β trap to the tumor microenvironment through its anti-PD-L1 component, which simultaneously attacks both the immunosuppressive PD-L1 and TGF-β entities, resulting in anti-tumor effect (83). A report by Zhou et al. indicated that an immunosuppressive subtype of tumor featured high immune infiltration, stromal enrichment, and TGF-β signaling pathway activation, which is likely suitable for anti-PD-L1 and anti-TGF-β combined therapy (84).
Figure 2 Macrophage depletion is a potential target between tumor associated macrophages (TAMs) and CD8-positive (CD8+) T cells, which holds back the immunosuppressive function of TAMs. The CC-chemokine receptor 2 (CCR2) and colony-stimulating factor 1 receptor (CSF1R) are key factors for macrophage recruitment and migration. Studies have suggested that inhibition of TAM recruitment enhances the efficacy of immune checkpoint therapy (A). Other studies have suggested that the chimeric antigen receptor T (CAR-T) cell overexpresses CAR-T cells with IL-12, causing TAM death through the FAS/FASL pathway, and anti-folate receptor β (FRβ) CAR-T cells have lethality toward TAMs (B).
In CAR-T therapy, a decrease in the numbers of TAM/Ms also demonstrates potency to reverse anti-immune status. IL-12, a cytokine that helps regulate innate immune cells, including macrophages and NK cells, can promote anti-tumor activity effectively. When IL-12 is co-expressed in CAR-T cells with neoantigens, it allows CAR-T cells the ability to regulate TAM/Ms through its feedback mechanisms. Agliardi et al. found that local delivery of IL-12 may be an effective adjuvant for CAR-T cell therapy for GBM (85). Also, in vivo and in vitro experiments have confirmed that simultaneous use of recombinant IL-12 can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors (86).
In an ovarian cancer study, CAR-T cells that allow the identification of tumor neoantigens were modified to secrete IL-12. The survival of patients was prolonged among those treated with the modified CAR-T cells, compared with the group without IL-12 secretion (87). In this case, IL-12 secretion is more likely to be autocrine, as demonstrated in studies with IL-12 receptor-knockout mice (87). On further evaluating the mechanisms underlying IL-12-related CAR-T-boosting effect, IL-12 overexpression in CAR-T cells demonstrated that an increase in the first apoptosis signal ligand (FASL), and thus an increase in the recognition of the first apoptosis signal (FAS) in macrophages, induces TAM/M apoptosis and thereby causes depletion of TAM/Ms (87). These results suggest that the modification of IL-12 expression can cause TAM/M depletion through the FAS/FASL pathway. Moreover, a negative feedback loop develops between CAR-T and TAM/Ms to maintain regulated immune homeostasis, which helps maximize the anti-tumor effect of CAR-T. Moreover, overexpression of IL-12 can help stimulate the cytotoxic effect of CD8+ T cells, which helps further boost the therapeutic effect of CAR-T cells (88) (Figure 2B). Another research team has reported that adding another TAM CAR target on folate receptor β (FRβ), which is highly expressed on TAM/Ms, can cause TAM/Ms to be eliminated in ovarian tumors and tumor growth may be delayed (Figure 2B). However, more studies are needed to develop CAR-T cell lines with two CAR systems on it. These studies suggest that TAM/Ms should be paid attention to during CAR-T cell treatment and co-treatment targeting TAM/Ms can help boost the effect of CAR-T therapy. Furthermore, there are other drugs that are designed for cardiovascular diseases, infections, and osteoporosis, namely telmisartan, minocycline, and zoledronic, respectively. These have been demonstrated to interfere with CCL2 synthesis, and therefore, may be associated with GBM treatment with a noncytotoxic regimen (89).
TAM/M Reprogramming
Although activated TAM/Ms are in the end stage of differentiation, they maintain their plasticity to reprogram their characteristics, which is a hallmark of macrophages. As an example, M2 macrophages are able to shift their phenotype to M1 when they are cultured in an inflammatory signal-enriched environment, such as with lipopolysaccharides and IFN-γ (90). As the GBM microenvironment exhibits a pro-M2 phenotype, which is predominantly immunosuppressive, reprogramming TAM/M differentiation to a pro-inflammatory status may be a possible mechanism with which to re-activate suppressed CD8+ T cells.
Failure of the immune checkpoint inhibitor (ICPi) to treat GBM underscores the need for improving the therapeutic strategy, and changing TAM from the M2 type (anti-inflammatory) to M1 (pro-inflammatory) type. This helps increase the therapeutic response of ICPi, and therefore, may be a promising therapeutic strategy. Hsu et al. (91) determined that combining rapamycin (R) and hydroxychloroquine (Q) preferentially induces M2 cell death, and in vitro RQ treatment decreases macrophage polarization of M2, whereas a combination of RQ and anti-PD1 treatment was found to be synergistic in action, and enhanced the intra-tumoral M1/M2 ratio. This provides a rationale for manipulating the TAM phenotype, as well as increasing the therapeutic effect of ICPi in GBM.
The macrophage-specialized pattern receptor macrophage receptor with collagenous structure (MARCO) is known to be specifically expressed in TAM/Ms. Recognition of the MARCO target pattern leads to reprograming of the suppressive phenotype of TAM/Ms (92). Studies have determined that MACRO-targeted antibodies can help intensify the efficacy of CTL4 antibody treatment, and thus enhance the power of immune checkpoint therapy that helps suppress tumor growth in the breast, colon, and skin. This helps reprogram macrophages against immunosuppression, which plays a role in boosting the anti-cancer ability of CD8+ T cells (92). The anti-MACRO antibody treatment reduces IL-10 expression, which helps trigger a decline in IL-1β. These cascaded cytokine fluctuations cause the TAM/M phenotype to shift from the immunosuppressive subtype to the immunostimulant subtype, thereby changing the tumor microenvironment to a pro-inflammatory phase and promoting the cytosis effect of CD8+ T cells in immune checkpoint inhibitor therapy. Phosphoinositide 3-kinase γ (PI3Kγ), a common differentiation regulator signal, also has a vital function in macrophage polarization. A previous study reported that treatment with the PD-L1 antibody significantly increased the infiltration of CD163+ macrophages in an in vivo GBM mouse model (31). However, the combined treatment with PD-L1 antibody and PI3Kγ inhibitor reversed the predominance of CD163, which helped boost PD-L1 antibody treatment. Immune checkpoint therapy, combined with macrophage reprograming, can help break the negative feedback induced by PD-1/PD-L1 treatment. Furthermore, treatment with PI3Kγ inhibitor reduced IL-10 and ARG1 expression in macrophages, as well as TGF-β, which enhanced the cytotoxicity of CD8+ T cells in a Lewis lung carcinoma model (93). These results suggest that the PI3Kγ inhibitor can help boost the efficacy of CD8+ T cells by reprogramming TAM/Ms and reshaping the immunosuppressive environment. Similar results have been reported in head and neck cancers as well (93). TMP195, a IIa histone deacetylase antagonist, has been proven to alter macrophage polarization from a tumor-suppressive phenotype to a classical scavenger phenotype (94). Further investigation suggested that co-treatment with the PD-1 antibody and TMP195 demonstrates improved tumor inhibition in a mouse breast cancer model (Figure 3A).
Figure 3 Macrophage reprogramming as a potential target between tumor associated macrophages (TAMs) and CD8-positive (CD8+) T cells. Macrophage reprogramming of TAMs can help shift the microenvironment from an immunosuppressive phenotype to a pro-inflammatory phenotype. In immune checkpoint therapy, macrophage receptors with a collagenous structure (MARCO), phosphoinositide 3-kinase γ (PI3Kγ), and histone deacetylase have been proven as targets that enhance the efficacy of immune checkpoint inhibitors through macrophage reprogramming (A). In chimeric antigen receptor T cell (CAR-T) therapy, CAR-T cells can reprogram TAMs by overexpressing IL-12 to boost its cytotoxicity (B).
In CAR-T therapy, T cells are sometimes suppressed via a supportive anti-immune environment, in which TAM/Ms have a major role in GBM. In a mouse tumor model with CEA overexpression, CEA-CAR-T cells demonstrated anti-cancer effects after CAR-T cell injection. However, the degree of cytotoxicity was similar to when the same CAR-T cells were injected into mice with a non-CEA-related cancer. Interestingly, co-expression of IL-12 on CEA-CAR-T cells significantly enhanced the tumor-killing effect of CAR-T cells in a CEA-dependent cancer. A similar effect of IL-12 co-expression was also found in a non-CEA-related cancer (95). It has been suggested that there are underlying IL-12-related factors that help boost the cytotoxic effect of CAR-T cells. Further investigation has demonstrated that IL-12 overexpression increases macrophage infiltration. Unlike classical TAM/Ms, IL-12-dependent macrophages are identical to the pro-inflammatory phenotype, which alters the immunosuppressive microenvironment induced by the predominance of the M2 phenotype macrophage. IL-12-dependent macrophage infiltration enhances the CAR-T effect with synergistic effects via multiple immune response pathways. Moreover, given the pro-inflammatory subtype, IL-12-dependent macrophages can directly kill tumor cells via TNF-α secretion. Another study wherein IL-12 was directly injected into mice with lung cancer showed that the IL-12 injection reduced IL-10 and TGF-β levels at the tumor site, which are considered to be signals of the M2 TAM/M phenotype, and increased the expression of IL-6 and TNF-α (96). These studies suggest that TAM/M reprograming helps enhance the anti-tumor effect of CAR-T therapy by altering the immune inhibition environment created by TAM/Ms (Figure 3B).
In anti-PD-1 therapy, various studies have validated that the therapeutic effect of anti-PD-1 blockade in GBM is mediated via the innate immune system, rather than by CD8+ T cells. Anti-PD-1 immunologically modulates innate immunity in the glioma microenvironment, which is likely a key mode of activity (97, 98). In a multicohort, phase 1b study, an anti-PD-1 immunotherapy using pembrolizumab demonstrated durable antitumor activity among a subset of PD-L1-positive, recurrent glioblastoma patients (99). Furthermore, previous studies have demonstrated that combination therapy with anti-PD-1 improves GBM outcomes. Saha et al. (100) demonstrated that the triple combination of anti-CTLA-4, anti-PD-1, and G47Δ-mIL12 healed most mice in the two glioma models. This treatment is related to macrophage influx and M1-like polarization, along with increased T effector to T regulatory cell ratios. In addition, CD4+ and CD8+ T cells, as well as macrophages, are required for synergistic curative activity. Wu et al. determined that combination immunotherapy comprising anti-CXCR4 and anti-PD-1 provides a survival benefit in GBM through immune cell modulation of the tumor microenvironment (101). These studies have shown that targeting differentiation signals of TAM/Ms can help reverse TAM/M functions from an immunosuppressive to an anti-tumor state, which disturbs the M2 TAM/M function and changes CD8+ T cell homeostasis. Overall, this enhances the cytotoxic effect of CD8+ T cells against GBM cells.
TAM/M-Derived Factors
In general, interaction between TAM/Ms and CD8+ T cells are thought to be counteractive. To activate the suppressive anti-tumor ability of CD8+ T cells, there are other potential pathways that need to be explored. A recent study demonstrated that the Fcγ receptor (FcγR), an immunoglobin receptor, has potential as an intervening target to renew TAM/M and CD8+ T cell crosstalk. In a colon cancer model, injection of anti-PD-1 antibodies was hypothesized to target PD-1 on the surface of CD8+ T cells, which helps reverse immunosuppression. However, anti-PD-1 antibodies were found to be recaptured by TAM/Ms via FcγR, which indicates another mechanism by which TAM/Ms help maintain an immunosuppressive microenvironment in immune checkpoint therapy (102). Further research has shown that a combination of anti PD-1 antibody and anti-FcγR antibody results in a much higher tumor inhibition rate than monotherapy with anti PD-1 antibody.
Another promising target is arginase-1 (ARG-1), which is known to be overexpressed in the M2 phenotype of macrophages as a potential biomarker (103). ARG-1 is an L-arginine enzyme that has been proven to have the capability of suppressing CD8+ T cell function through L-arginine depletion (66). High ARG-1-expressing TAM/Ms that are separated from the orthotopic pulmonary fibrosarcoma can also inhibit the proliferation of T cells (104, 105). An in vivo study demonstrated that treatment with anti-CTL4 antibody, in combination with the ARG-1 inhibitor CB-1158, significantly inhibited tumor growth in a lung metastasis mouse model (106). Likewise, similar results were reported with co-treatment with anti-PD-1 antibody and CB-1158 in a mouse model of colon cancer (92).
Signal transducers and activators of transcription 3 (STAT3) pathway is not only a growth controlling factor of GBM cells (107) but also a signal that regulates transcription of CD86 and CD80, as well as several macrophage-related target genes (108). Injecting small interfering RNA (siRNA) targeting STAT3 in GBM-bearing mice demonstrated promising results with respect to TNF-α-related macrophages, thereby altering the immunosuppressive environment to an optimal survival benefit (109) (Figure 4).
Figure 4 Tumor-associated macrophages (TAMs) factor as potential targets to overcome CD8-positive (CD8+) T cells suppression. The Fcγ receptor (FcγR) has been tested in vivo as a target for TAMs-CD8+ T cell interaction. Arginase-1 (ARG-1) can regulate CD8+ T cell metabolism via L-arginine depletion.
Interestingly, GBM and M2-like immunosuppressive macrophages promote angiogenesis, whereas M1-like pro-inflammatory macrophages suppress angiogenesis, which is known as “inflammation-driven angiogenesis”. Furthermore, soluble immunosuppressive cytokines, including predominantly TGF-β1 (which inhibits CD8+T cell), and surface integrin (αvβ3) endothelial-macrophage interactions are required in inflammation-driven angiogenesis. Therefore, dual αvβ3 and cytokine receptor (TGFβ-R1) blockade suppresses GBM tumor neovascularization by simultaneously targeting macrophage-associated immunosuppression and endothelial-macrophage interactions (110). Additionally, targeting TGF-β1 and TGF-β2 may improve intratumoral T cell infiltration and thus, enhance the effectiveness of immunotherapeutic approaches in GBM (111).
Conclusion and Perspectives
There has been significant discussion regarding the immune system in the CNS over the past decade. However, the real situation has not been clearly described. The crosstalk between TAM/Ms and CD8+ T cells is still very important in the GBM immune response. Many potential targets have been studied for improving the prognosis of GBM patients and for disease prevention. Several studies have been successfully translated into clinical practice with promising results. Nevertheless, GBM, a malignant disease of the CNS, is still hard to treat. More studies are required to uncover the mechanisms associated with the symphonic immune interactions in GBM.
In this review, we discussed the role of TAM/Ms and CD8+ T cells in GBM, as well as the interactions between them. TAM/Ms in GBM are dominant in their anti-inflammatory phenotype, which is the main effector responsible for creating an immunosuppressive GBM microenvironment. TAM/Ms are able to inhibit the cytotoxic effect of CD8+ T cells through a multitude of biological pathways and cytokines. This suppressive process not only appears amidst development of GBM but also appears during the application of GBM treatment.
There are potential therapeutic targets that underlie the crosstalk between TAM/Ms and CD8+ T cells. Sabotaging TAM/M recruitment and migration can cause the depletion of TAM/Ms, which helps revive the cytotoxic effect of CD8+ T cells that can help lead the fight against GBM cells. CCL2 and CSF-1 inhibitor have shown significant potential for further clinical evaluation to improve CTL-related immune therapies, such as immune checkpoint inhibitor therapy, and CAR-T therapy. To reverse the immunosuppressive situation in the GBM tissue, reprograming TAM/Ms can help shift TAM/Ms from an anti-inflammatory phenotype, toward a pro-inflammatory phenotype, enhancing the CD8+ function of CTLs. IL-10, IL-12, and PI3Kγ have a significant function in this process. Furthermore, biological agents can be used to boost suitable therapies. Moreover, novel TAM factors have been tested with optimal results, as anti-tumor targets. Interactions between TAM/Ms and CD8+ T cells were considered to have a decisive power in GBM physiology, as well as immune therapy for GBM. Finally, the underlying targets for GBM therapy need to be further studied to clinically improve the outcomes of GBM patients.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Author Contributions
YZ and AS conceptualized the research project. ST, XL, AS, and JZ wrote the paper and made the original figures. ST, HW, YY, JQ, SH, and YW critically revised the texts and figures. AS, YD, and YZ supervised the research and led the discussion. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by National Natural Science Foundation of China (81701144) and Zhejiang Provincial Natural Science Foundation of China (LQ19H160045).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
BBB, blood–brain barrier; CAR-T, chimeric antigen receptor T cell; CCL2, chemotactic protein-1; CD68, clusters of differentiation 68; CD8+, CD8 positive; CNS, central nervous system; CSF1R, colony-stimulating factor 1 receptor; CTL, cytotoxic lymphocytes; DAMPs, damage-associated molecular patterns; DC, dendritic cells; FAS, first apoptosis signal; FASL, first apoptosis signal ligand; FcγR, Fcγ receptor; FRβ,folate receptor β; GBM, glioblastoma multiforme; ICI, immune checkpoint inhibitor; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-gamma; iNOs, inducible NO synthase; MARCO, macrophage receptor with collagenous structure; MCH-1, histocompatibility complex class I; PAMPs, pathogen-associated molecular patterns; TAMs, tumor associated macrophages; TAM/Ms, tumor-associated microglia/macrophages; TGF-β, tumor growth factor β; Treg, regulation T cells; VISTA, V-domain Ig suppressor of T cell activation.
References
1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol (2016) 131(6):803–20. doi: 10.1007/s00401-016-1545-1
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin (2019) 69(1):7–34. doi: 10.3322/caac.21551
3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. J Clin Oncol (2007) 25(26):4127–36. doi: 10.1200/JCO.2007.11.8554
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. Lancet Oncol (2009) 10(5):459–66. doi: 10.1016/S1470-2045(09)70025-7
5. Komin A, Bogorad MI, Lin R, Cui H, Searson PC, Hristova K. A Peptide for Transcellular Cargo Delivery: Structure-Function Relationship and Mechanism of Action. J Control Release (2020) 324:633–43. doi: 10.1016/j.jconrel.2020.05.030
6. Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and Genomic Correlates of Response to Anti-PD-1 Immunotherapy in Glioblastoma. Nat Med (2019) 25(3):462–9. doi: 10.1038/s41591-019-0349-y
7. Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of Glioblastoma: State of the Art and Future Directions. CA Cancer J Clin (2020) 70(4):299–312. doi: 10.3322/caac.21613
8. Jackson CM, Choi J, Lim M. Mechanisms of Immunotherapy Resistance: Lessons From Glioblastoma. Nat Immunol (2019) 20(9):1100–9. doi: 10.1038/s41590-019-0433-y
9. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively Personalized Vaccination Trial for Newly Diagnosed Glioblastoma. Nature (2019) 565(7738):240–5. doi: 10.1038/s41586-018-0810-y
10. Hanisch UK. Functional Diversity of Microglia - How Heterogeneous Are They to Begin With? Front Cell Neurosci (2013) 7:65. doi: 10.3389/fncel.2013.00065
11. Cassetta L, Kitamura T. Macrophage Targeting: Opening New Possibilities for Cancer Immunotherapy. Immunology (2018) 155(3):285–93. doi: 10.1111/imm.12976
12. Qian BZ, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell (2010) 141(1):39–51. doi: 10.1016/j.cell.2010.03.014
13. Annovazzi L, Mellai M, Bovio E, Mazzetti S, Pollo B, Schiffer D. Microglia Immunophenotyping in Gliomas. Oncol Lett (2018) 15(1):998–1006. doi: 10.3892/ol.2017.7386
14. Wolf SA, Boddeke HW, Kettenmann H. Microglia in Physiology and Disease. Annu Rev Physiol (2017) 79:619–43. doi: 10.1146/annurev-physiol-022516-034406
15. Kabba JA, Xu Y, Christian H, Ruan W, Chenai K, Xiang Y, et al. Microglia: Housekeeper of the Central Nervous System. Cell Mol Neurobiol (2018) 38(1):53–71. doi: 10.1007/s10571-017-0504-2
16. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and Differentiation of Microglia. Front Cell Neurosci (2013) 7:45. doi: 10.3389/fncel.2013.00045
17. Amici SA, Dong J, Guerau-de-Arellano M. Molecular Mechanisms Modulating the Phenotype of Macrophages and Microglia. Front Immunol (2017) 8:1520. doi: 10.3389/fimmu.2017.01520
18. Nakagawa Y, Chiba K. Diversity and Plasticity of Microglial Cells in Psychiatric and Neurological Disorders. Pharmacol Ther (2015) 154:21–35. doi: 10.1016/j.pharmthera.2015.06.010
19. Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 Polarization and Metabolic States. Br J Pharmacol (2016) 173(4):649–65. doi: 10.1111/bph.13139
20. Li S, Liu M, Do MH, Chou C, Stamatiades EG, Nixon BG, et al. Cancer Immunotherapy via Targeted TGF-β Signalling Blockade in T(H) Cells. Nature (2020) 587(7832):121–5. doi: 10.1038/s41586-020-2850-3
21. Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, et al. The Construction, Expression, and Enhanced Anti-Tumor Activity of YM101: A Bispecific Antibody Simultaneously Targeting TGF-β and PD-L1. J Hematol Oncol (2021) 14(1):27. doi: 10.1186/s13045-021-01045-x
22. Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H. Anti-TGF-β Antibody Combined With Dendritic Cells Produce Antitumor Effects in Osteosarcoma. Clin Orthop Relat Res (2012) 470(8):2288–94. doi: 10.1007/s11999-012-2299-2
23. Terabe M, Ambrosino E, Takaku S, O’Konek JJ, Venzon D, Lonning S, et al. Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-Beta Monoclonal Antibody. Clin Cancer Res (2009) 15(21):6560–9. doi: 10.1158/1078-0432.CCR-09-1066
24. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An Anti-Transforming Growth Factor Beta Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments. Cancer Res (2008) 68(10):3835–43. doi: 10.1158/0008-5472.CAN-08-0215
25. Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune Microenvironment of Gliomas. Lab Invest (2017) 97(5):498–518. doi: 10.1038/labinvest.2017.19
26. Fahey JM, Korytowski W, Girotti AW. Upstream Signaling Events Leading to Elevated Production of Pro-Survival Nitric Oxide in Photodynamically-Challenged Glioblastoma Cells. Free Radic Biol Med (2019) 137:37–45. doi: 10.1016/j.freeradbiomed.2019.04.013
27. Hambardzumyan D, Gutmann DH, Kettenmann H. The Role of Microglia and Macrophages in Glioma Maintenance and Progression. Nat Neurosci (2016) 19(1):20–7. doi: 10.1038/nn.4185
28. Matias D, Dubois LG, Pontes B, Rosario L, Ferrer VP, Balca-Silva J, et al. GBM-Derived Wnt3a Induces M2-Like Phenotype in Microglial Cells Through Wnt/beta-Catenin Signaling. Mol Neurobiol (2019) 56(2):1517–30. doi: 10.1007/s12035-018-1150-5
29. Martinez-Lage M, Lynch TM, Bi Y, Cocito C, Way GP, Pal S, et al. Immune Landscapes Associated With Different Glioblastoma Molecular Subtypes. Acta Neuropathol Commun (2019) 7(1):203. doi: 10.1186/s40478-019-0803-6
30. Lau SK, Chu PG, Weiss LM. CD163: A Specific Marker of Macrophages in Paraffin-Embedded Tissue Samples. Am J Clin Pathol (2004) 122(5):794–801. doi: 10.1309/QHD6YFN81KQXUUH6
31. Miyazaki T, Ishikawa E, Matsuda M, Sugii N, Kohzuki H, Akutsu H, et al. Infiltration of CD163-Positive Macrophages in Glioma Tissues After Treatment With Anti-PD-L1 Antibody and Role of PI3Kgamma Inhibitor as a Combination Therapy With Anti-PD-L1 Antibody in In Vivo Model Using Temozolomide-Resistant Murine Glioma-Initiating Cells. Brain Tumor Pathol (2020) 37(2):41–9. doi: 10.1007/s10014-020-00357-z
32. Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 108(11). doi: 10.1093/jnci/djw144
33. Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, et al. Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas is Superior to Histological Diagnosis. Clin Cancer Res (2007) 13(24):7341–56. doi: 10.1158/1078-0432
34. Vauleon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, et al. Immune Genes are Associated With Human Glioblastoma Pathology and Patient Survival. BMC Med Genomics (2012) 5:41. doi: 10.1186/1755-8794-5-41
35. Lisi L, Ciotti GM, Braun D, Kalinin S, Curro D, Dello Russo C, et al. Expression of iNOS, CD163 and ARG-1 Taken as M1 and M2 Markers of Microglial Polarization in Human Glioblastoma and the Surrounding Normal Parenchyma. Neurosci Lett (2017) 645:106–12. doi: 10.1016/j.neulet.2017.02.076
36. Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, et al. Depletion of Tumor-Associated Macrophages With a CSF-1r Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy. Cancer Immunol Res (2017) 5(7):535–46. doi: 10.1158/2326-6066.CIR-16-0309
37. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med (2012) 18:519–27. doi: 10.2119/molmed.2011.00217
38. Leivonen SK, Kahari VM. Transforming Growth Factor-Beta Signaling in Cancer Invasion and Metastasis. Int J Cancer (2007) 121(10):2119–24. doi: 10.1002/ijc.23113
39. Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Kristensen BW. Tumour-Associated Microglia/Macrophages Predict Poor Prognosis in High-Grade Gliomas and Correlate With an Aggressive Tumour Subtype. Neuropathol Appl Neurobiol (2018) 44(2):185–206. doi: 10.1111/nan.12428
40. González-Tablas Pimenta M, Otero Á, Arandia Guzman DA, Pascual-Argente D, Ruíz Martín L, Sousa-Casasnovas P, et al. Tumor Cell and Immune Cell Profiles in Primary Human Glioblastoma: Impact on Patient Outcome. Brain Pathol (2020) 31(2):365–80. doi: 10.1111/bpa.12927
41. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible Involvement of the M2 Anti-Inflammatory Macrophage Phenotype in Growth of Human Gliomas. J Pathol (2008) 216(1):15–24. doi: 10.1002/path.2370
42. Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velázquez Vega JE, et al. Human Mesenchymal Glioblastomas are Characterized by an Increased Immune Cell Presence Compared to Proneural and Classical Tumors. Oncoimmunology (2019) 8(11):e1655360. doi: 10.1080/2162402X.2019.1655360
43. Li J, Kaneda MM, Ma J, Li M, Shepard RM, Patel K, et al. Pi3kγ Inhibition Suppresses Microglia/TAM Accumulation in Glioblastoma Microenvironment to Promote Exceptional Temozolomide Response. Proc Natl Acad Sci USA (2021) 118(16). doi: 10.1101/2020.05.14.097121
44. Wang J, Leavenworth JW, Hjelmeland AB, Smith R, Patel N, Borg B, et al. Deletion of the RNA Regulator HuR in Tumor-Associated Microglia and Macrophages Stimulates Anti-Tumor Immunity and Attenuates Glioma Growth. Glia (2019) 67(12):2424–39. doi: 10.1002/glia.23696
45. Martins TA, Schmassmann P, Shekarian T, Boulay JL, Ritz MF, Zanganeh S, et al. Microglia-Centered Combinatorial Strategies Against Glioblastoma. Front Immunol (2020) 11:571951. doi: 10.3389/fimmu.2020.571951
46. Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, et al. Adoptive CD8(+) T Cell Therapy Against Cancer:Challenges and Opportunities. Cancer Lett (2019) 462:23–32. doi: 10.1016/j.canlet.2019.07.017
47. Ratnam NM, Gilbert MR, Giles AJ. Immunotherapy in CNS Cancers: The Role of Immune Cell Trafficking. Neuro Oncol (2019) 21(1):37–46. doi: 10.1093/neuonc/noy084
48. Brown KA. Factors Modifying the Migration of Lymphocytes Across the Blood-Brain Barrier. Int Immunopharmacol (2001) 1(12):2043–62. doi: 10.1016/S1567-5769(01)00129-1
49. Beier CP, Kumar P, Meyer K, Leukel P, Bruttel V, Aschenbrenner I, et al. The Cancer Stem Cell Subtype Determines Immune Infiltration of Glioblastoma. Stem Cells Dev (2012) 21(15):2753–61. doi: 10.1089/scd.2011.0660
50. Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, et al. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth. Cells (2020) 9(4). doi: 10.3390/cells9040998
51. Rahman M, Sawyer WG, Lindhorst S, Deleyrolle LP, Harrison JK, Karachi A, et al. Adult Immuno-Oncology: Using Past Failures to Inform the Future. Neuro Oncol (2020) 22(9):1429–61. doi: 10.1093/neuonc/noaa116
52. Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, et al. Immunological Analysis of Phase II Glioblastoma Dendritic Cell Vaccine (Audencel) Trial: Immune System Characteristics Influence Outcome and Audencel Up-Regulates Th1-Related Immunovariables. Acta Neuropathol Commun (2018) 6(1):135. doi: 10.1186/s40478-018-0621-2
53. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, et al. CD8+ T-Cell Infiltrate in Newly Diagnosed Glioblastoma Is Associated With Long-Term Survival. J Clin Neurosci (2010) 17(11):1381–5. doi: 10.1016/j.jocn.2010.03.031
54. Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, et al. Increased Proportion of FoxP3+ Regulatory T Cells in Tumor Infiltrating Lymphocytes is Associated With Tumor Recurrence and Reduced Survival in Patients With Glioblastoma. Cancer Immunol Immunother (2015) 64(4):419–27. doi: 10.1007/s00262-014-1651-7
55. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas Promote Immunosuppression Through Induction of B7-H1 Expression in Tumor-Associated Macrophages. Clin Cancer Res (2013) 19(12):3165–75. doi: 10.1158/1078-0432.CCR-12-3314
56. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab With or Without Ipilimumab in Patients With Recurrent Glioblastoma: Results From Exploratory Phase I Cohorts of CheckMate 143. Neuro Oncol (2018) 20(5):674–86. doi: 10.1093/neuonc/nox208
57. Thomas DA, Massague J. TGF-Beta Directly Targets Cytotoxic T Cell Functions During Tumor Evasion of Immune Surveillance. Cancer Cell (2005) 8(5):369–80. doi: 10.1016/j.ccr.2005.10.012
58. Lee GR. The Balance of Th17 Versus Treg Cells in Autoimmunity. Int J Mol Sci (2018) 19(3). doi: 10.3390/ijms19030730
59. Proto JD, Doran AC, Gusarova G, Yurdagul A Jr., Sozen E, Subramanian M, et al. Regulatory T Cells Promote Macrophage Efferocytosis During Inflammation Resolution. Immunity (2018) 49(4):666–77 e6. doi: 10.1016/j.immuni.2018.07.015
60. Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. Control of Tumor-Associated Macrophages and T Cells in Glioblastoma via AHR and CD39. Nat Neurosci (2019) 22(5):729–40. doi: 10.1038/s41593-019-0370-y
61. Jiang H, Hegde S, DeNardo DG. Tumor-Associated Fibrosis as a Regulator of Tumor Immunity and Response to Immunotherapy. Cancer Immunol Immunother (2017) 66(8):1037–48. doi: 10.1007/s00262-017-2003-1
62. Wynn TA, Barron L. Macrophages: Master Regulators of Inflammation and Fibrosis. Semin Liver Dis (2010) 30(3):245–57. doi: 10.1055/s-0030-1255354
63. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer Res (2016) 76(19):5671–82. doi: 10.1158/0008-5472.CAN-16-0144
64. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R Inhibition Alters Macrophage Polarization and Blocks Glioma Progression. Nat Med (2013) 19(10):1264–72. doi: 10.1038/nm.3337
65. Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res (2018) 78(15):4253–69. doi: 10.1158/0008-5472.CAN-17-3876
66. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity (2014) 41(1):49–61. doi: 10.1016/j.immuni.2014.06.010
67. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, et al. Comparison of Immune Infiltrates in Melanoma and Pancreatic Cancer Highlights VISTA as a Potential Target in Pancreatic Cancer. Proc Natl Acad Sci USA (2019) 116(5):1692–7. doi: 10.1073/pnas.1811067116
68. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant Anti-PD-1 Immunotherapy Promotes a Survival Benefit With Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma. Nat Med (2019) 25(3):477–86. doi: 10.1038/s41591-018-0337-7
69. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients With Recurrent Glioblastoma. Clin Cancer Res (2015) 21(18):4062–72. doi: 10.1158/1078-0432.CCR-15-0428
70. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A Single Dose of Peripherally Infused EGFRvIII-Directed CAR T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients With Recurrent Glioblastoma. Sci Transl Med (2017) 9(399). doi: 10.1126/scitranslmed.aaa0984
71. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma After Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med (2016) 375(26):2561–9. doi: 10.1056/NEJMoa1610497
72. Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al. CCL2-Induced Chemokine Cascade Promotes Breast Cancer Metastasis by Enhancing Retention of Metastasis-Associated Macrophages. J Exp Med (2015) 212(7):1043–59. doi: 10.1084/jem.20141836
73. Komiya H, Takeuchi H, Ogawa Y, Hatooka Y, Takahashi K, Katsumoto A, et al. CCR2 Is Localized in Microglia and Neurons, as Well as Infiltrating Monocytes, in the Lumbar Spinal Cord of ALS Mice. Mol Brain (2020) 13(1):64. doi: 10.1186/s13041-020-00607-3
74. Lu X, Kang Y. Chemokine (C-C Motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone. J Biol Chem (2009) 284(42):29087–96. doi: 10.1074/jbc.M109.035899
75. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 Recruits Inflammatory Monocytes to Facilitate Breast-Tumour Metastasis. Nature (2011) 475(7355):222–5. doi: 10.1038/nature10138
76. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S, et al. Monocyte Chemoattractant Protein-1 Increases Microglial Infiltration and Aggressiveness of Gliomas. Ann Neurol (2003) 54(3):388–92. doi: 10.1002/ana.10679
77. Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, et al. Therapeutic Targeting of Macrophages Enhances Chemotherapy Efficacy by Unleashing Type I Interferon Response. Nat Cell Biol (2019) 21(4):511–21. doi: 10.1038/s41556-019-0298-1
78. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery (2011) 1(1):54–67. doi: 10.1158/2159-8274.CD-10-0028
79. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R Inhibition Delays Cervical and Mammary Tumor Growth in Murine Models by Attenuating the Turnover of Tumor-Associated Macrophages and Enhancing Infiltration by CD8(+) T Cells. Oncoimmunology (2013) 2(12):e26968. doi: 10.4161/onci.26968
80. Held-Feindt J, Hattermann K, Muerkoster SS, Wedderkopp H, Knerlich-Lukoschus F, Ungefroren H, et al. CX3CR1 Promotes Recruitment of Human Glioma-Infiltrating Microglia/Macrophages (GIMs). Exp Cell Res (2010) 316(9):1553–66. doi: 10.1016/j.yexcr.2010.02.018
81. Mercurio L, Ajmone-Cat MA, Cecchetti S, Ricci A, Bozzuto G, Molinari A, et al. Targeting CXCR4 by a Selective Peptide Antagonist Modulates Tumor Microenvironment and Microglia Reactivity in a Human Glioblastoma Model. J Exp Clin Cancer Res (2016) 35:55. doi: 10.1186/s13046-016-0326-y
82. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Res (2013) 73(3):1128–41. doi: 10.1158/0008-5472.CAN-12-2731
83. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, et al. Dual Targeting of TGF-β and PD-L1 via a Bifunctional Anti-PD-L1/TGF-βrii Agent: Status of Preclinical and Clinical Advances. J Immunother Cancer (2020) 8(1). doi: 10.1136/jitc-2019-000433
84. Zhou YJ, Zhu GQ, Lu XF, Zheng KI, Wang QW, Chen JN, et al. Identification and Validation of Tumour Microenvironment-Based Immune Molecular Subgroups for Gastric Cancer: Immunotherapeutic Implications. Cancer Immunol Immunother (2020) 69(6):1057–69. doi: 10.1007/s00262-020-02525-8
85. Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Núñez N, Stowe CL, et al. Intratumoral IL-12 Delivery Empowers CAR-T Cell Immunotherapy in a Pre-Clinical Model of Glioblastoma. Nat Commun (2021) 12(1):444. doi: 10.1038/s41467-020-20599-x
86. Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, et al. Significantly Increased Anti-Tumor Activity of Carcinoembryonic Antigen-Specific Chimeric Antigen Receptor T Cells in Combination With Recombinant Human IL-12. Cancer Med (2019) 8(10):4753–65. doi: 10.1002/cam4.2361
87. Portielje JE, Gratama J, van Ojik HH, Stoter G, Kruit WH. IL-12: A Promising Adjuvant for Cancer Vaccination. Cancer Immunol Immunother (2003) 52(3):133–44. doi: 10.1007/s00262-002-0356-5
88. Wraith DC. The Future of Immunotherapy: A 20-Year Perspective. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.01668
89. Salacz ME, Kast RE, Saki N, Bruning A, Karpel-Massler G, Halatsch ME. Toward a Noncytotoxic Glioblastoma Therapy: Blocking MCP-1 With the MTZ Regimen. Oncol Targets Ther (2016) 9:2535–45. doi: 10.2147/OTT.S100407
90. Smith TD, Tse MJ, Read EL, Liu WF. Regulation of Macrophage Polarization and Plasticity by Complex Activation Signals. Integr Biol (2016) 8(9):946–55. doi: 10.1039/c6ib00105j
91. Hsu SPC, Chen YC, Chiang HC, Huang YC, Huang CC, Wang HE, et al. Rapamycin and Hydroxychloroquine Combination Alters Macrophage Polarization and Sensitizes Glioblastoma to Immune Checkpoint Inhibitors. J Neurooncol (2020) 146(3):417–26. doi: 10.1007/s11060-019-03360-3
92. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Ostling J, et al. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep (2016) 15(9):2000–11. doi: 10.1016/j.celrep.2016.04.084
93. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kgamma Is a Molecular Switch That Controls Immune Suppression. Nature (2016) 539(7629):437–42. doi: 10.1038/nature19834
94. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC Inhibition Reduces Breast Tumours and Metastases Through Anti-Tumour Macrophages. Nature (2017) 543(7645):428–32. doi: 10.1038/nature21409
95. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. Cancer Res (2011) 71(17):5697–706. doi: 10.1158/0008-5472.CAN-11-0103
96. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 Rapidly Alters the Functional Profile of Tumor-Associated and Tumor-Infiltrating Macrophages In Vitro and In Vivo. J Immunol (2007) 178(3):1357–62. doi: 10.4049/jimmunol.178.3.1357
97. Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, et al. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res (2020) 26(17):4699–712. doi: 10.1158/1078-0432.CCR-19-4110
98. Wu S, Calero-Pérez P, Arús C, Candiota AP. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment With MRSI-Based Approaches. Int J Mol Sci (2020) 21(22). doi: 10.3390/ijms21228775
99. Reardon DA, Kim TM, Frenel JS, Simonelli M, Lopez J, Subramaniam DS, et al. Treatment With Pembrolizumab in Programmed Death Ligand 1-Positive Recurrent Glioblastoma: Results From the Multicohort Phase 1 KEYNOTE-028 Trial. Cancer (2021) 127(10):1620–9. doi: 10.1002/cncr.33378
100. Saha D, Martuza RL, Rabkin SD. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell (2017) 32(2):253–67. e5. doi: 10.1016/j.ccell.2017.07.006
101. Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, et al. Combination Anti-CXCR4 and Anti-PD-1 Immunotherapy Provides Survival Benefit in Glioblastoma Through Immune Cell Modulation of Tumor Microenvironment. J Neurooncol (2019) 143(2):241–9. doi: 10.1007/s11060-019-03172-5
102. Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. In Vivo Imaging Reveals a Tumor-Associated Macrophage-Mediated Resistance Pathway in Anti-PD-1 Therapy. Sci Transl Med (2017) 9(389). doi: 10.1126/scitranslmed.aal3604
103. Yamada KJ, Heim CE, Aldrich AL, Gries CM, Staudacher AG, Kielian T. Arginase-1 Expression in Myeloid Cells Regulates Staphylococcus Aureus Planktonic But Not Biofilm Infection. Infect Immun (2018) 86(7). doi: 10.1128/IAI.00206-18
104. Kusmartsev S, Gabrilovich DI. STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion. J Immunol (2005) 174(8):4880–91. doi: 10.4049/jimmunol.174.8.4880
105. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Res (2004) 64(16):5839–49. doi: 10.1158/0008-5472.CAN-04-0465
106. Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of Arginase by CB-1158 Blocks Myeloid Cell-Mediated Immune Suppression in the Tumor Microenvironment. J Immunother Cancer (2017) 5(1):101. doi: 10.1186/s40425-017-0308-4
107. Li W, Graeber MB. The Molecular Profile of Microglia Under the Influence of Glioma. Neuro Oncol (2012) 14(8):958–78. doi: 10.1093/neuonc/nos116
108. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 Signaling in the Hematopoietic System Elicits Multicomponent Antitumor Immunity. Nat Med (2005) 11(12):1314–21. doi: 10.1038/nm1325
109. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 Inhibition Activates Tumor Macrophages and Abrogates Glioma Growth in Mice. Glia (2009) 57(13):1458–67. doi: 10.1002/glia.20863
110. Cui X, Morales RT, Qian W, Wang H, Gagner JP, Dolgalev I, et al. Hacking Macrophage-Associated Immunosuppression for Regulating Glioblastoma Angiogenesis. Biomaterials (2018) 161:164–78. doi: 10.1016/j.biomaterials.2018.01.053
Keywords: tumor, microglia, macrophages, CD8-positive T cells, glioblastoma
Citation: Tu S, Lin X, Qiu J, Zhou J, Wang H, Hu S, Yao Y, Wang Y, Deng Y, Zhou Y and Shao A (2021) Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Front. Immunol. 12:650105. doi: 10.3389/fimmu.2021.650105
Received: 06 January 2021; Accepted: 21 June 2021;
Published: 29 July 2021.
Edited by:
Simrit Parmar, University of Texas MD Anderson Cancer Center, United StatesReviewed by:
Takashi MaruYama, National Institutes of Health (NIH), United StatesKai Yang, Indiana University School of Medicine, United States
Copyright © 2021 Tu, Lin, Qiu, Zhou, Wang, Hu, Yao, Wang, Deng, Zhou and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sheng Tu, 1234-5678@zju.edu.cn; Yunxiang Zhou, yxzhou@zju.edu.cn; Anwen Shao, shaoanwen@zju.edu.cn
†These authors have contributed equally to this work